Description
The sustained therapeutic benefit lasting at least 6 months from a single treatment is remarkable but mechanistically unexplained. Understanding whether this reflects circular RNA stability, epigenetic changes, or other factors is critical for optimizing dosing strategies and predicting long-term efficacy.
Gap type: unexplained_observation Source paper: Circular RNA aptamers targeting neuroinflammation ameliorate Alzheimer disease phenotypes in mouse models. (None, None, PMID:40164764)